ABBV was trading lower on friday after the the FDA pushed back the review period for the company's supplemental marketing application for upadacitinib in active psoriatic arthritis. Despite the big drop, it fell right to key support (right at the bottom of a range) making a good entry here in terms of RR, having a tight stop and aiming for the top of range (gap fill). For options, look for leaps.
Trade active
⋅
Added a swing position at open, looks great so far.
Trade closed: target reached
⋅
trimmed most of my position here and only have runner left. great profits!